奥翔药业:2024年报净利润2.07亿 同比下降18.5%

Financial Performance - The company's basic earnings per share decreased by 19.35% to 0.2500 yuan in 2024 from 0.3100 yuan in 2023 [1] - The net profit for 2024 was 2.07 billion yuan, down 18.5% from 2.54 billion yuan in 2023 [1] - The return on equity (ROE) fell to 9.40% in 2024, a decline of 26.16% compared to 12.73% in 2023 [1] - Total revenue for 2024 was 7.95 billion yuan, a decrease of 2.69% from 8.17 billion yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 49,379.58 million shares, accounting for 59.47% of the circulating shares, with a decrease of 399.67 million shares compared to the previous period [1] - The largest shareholder, Zheng Zhiguo, holds 42,043.37 million shares, representing 50.64% of the total share capital, with no change [2] - New entrants among the top shareholders include Wang Mian and Luo Taixiang, while Hong Kong Central Clearing Limited, Xu Haiyan, and Wang Jianguo exited the top ten shareholders [2] Dividend Distribution - The company announced a dividend distribution plan of 10 yuan per 1 share (including tax) [3]